This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.
ruxolitinib) up by 26%, spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi) up by 28%, and cancer medicine Kisqali (ribociclib), which grew by 27% in sales revenue.
Novartis has presented a final analysis of its phase 3 MONALEESA-2 trial showing a survival benefit of more than 12 months for its CDK4/6 inhibitor, Kisqali (ribociclib) in combination ... These remarkable ribociclib overall survival data are highly
Novartis also presented data from the phase 3 MONALEESA-3 trial analysing the efficacy and safety of Kisqali (ribociclib) in combination with fulvestrant in postmenopausal women with HR-positive/HER2-negative
Exploratory analysis of OS results for Kisqali (ribociclib) plus fulvestrant as a first- or second-line treatment compared to fulvestrant alone in this patient population found that the Kisqali combination continued
In addition, sales of the company’s plaque psoriasis treatment Cosentyx (secukinumab) increased by 7%, with its HER2-negative breast cancer therapy Kisqali (ribociclib) also growing by 50%.
According to NICE, Ibrance now joins two other of its approved drugs – Novartis’ Kisqali (ribociclib) and Lilly’s Verzenio (abemaciclib) - as a treatment option for patients at this stage of the
More from news
Approximately 4 fully matching, plus 37 partially matching documents found.
East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...